MCM
AIDX

MAI Capital Management’s 20/20 Biolabs Inc AIDX Stock Holding History

MAI Capital Management’s Portfolio AIDX Stock Details AIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,000
Closed -$1.88K – 5104
2026
Q1 		$1.88K Buy
+1,000
New +$4.22K ﹤0.01% 3951

Other funds holding AIDX

CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.99B AUM 23.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MP
McDonald Partners Cleveland, Ohio $412M AUM 34.27% 1-Year Est. Return

MAI Capital Management's AIDX Position: Q2 2026 in Review

MAI Capital Management sold out of 20/20 Biolabs Inc (AIDX) in Q2 2026, closing a stake of 1,000 shares — an estimated $1.88K sold.

MAI Capital Management first reported a position in AIDX in Q1 2026 and held it in 1 quarter. The position peaked at $1.88K in Q1 2026. 15 funds tracked by Wall St. Rank hold AIDX as of Q2 2026.

  • MAI Capital Management reported no remaining 20/20 Biolabs Inc position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,000 20/20 Biolabs Inc shares in Q2 2026, an estimated $1.88K.
  • MAI Capital Management first reported a position in 20/20 Biolabs Inc in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's 20/20 Biolabs Inc position peaked at $1.88K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held 20/20 Biolabs Inc as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.